{"id":727872,"date":"2023-02-01T16:34:57","date_gmt":"2023-02-01T21:34:57","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-to-report-fourth-quarter-and-full-year-2022-financial-results-on-march-15-2023-and-participate-in-upcoming-investor-conferences\/"},"modified":"2023-02-01T16:34:57","modified_gmt":"2023-02-01T21:34:57","slug":"maxcyte-to-report-fourth-quarter-and-full-year-2022-financial-results-on-march-15-2023-and-participate-in-upcoming-investor-conferences","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-to-report-fourth-quarter-and-full-year-2022-financial-results-on-march-15-2023-and-participate-in-upcoming-investor-conferences\/","title":{"rendered":"MaxCyte to Report Fourth Quarter and Full Year 2022 Financial Results on March 15, 2023 and Participate in Upcoming Investor Conferences"},"content":{"rendered":"<div class=\"mw_release\">\n<p>ROCKVILLE, Md., Feb.  01, 2023  (GLOBE NEWSWIRE) &#8212; MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support innovative cell-based research, today announced that it will release financial results for the fourth quarter and full year 2022 after the U.S. market close on Wednesday, March 15<sup>th<\/sup>, 2023. Company management will host a conference call to discuss financial results at 4:30 p.m. Eastern Time.<\/p>\n<p>\n        <strong>Earnings Conference Call Details<\/strong><br \/>\n        <br \/>Investors interested in listening to the conference call are required to <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=qYisYT_NU4aol0qrTVO6bMu8XXWUWv4pAFW4PfEH3cJOBsPx9YhVPJS2tY_SzpRgqf4jOW8ejSIIusHzLIoKRLRbo6qbX6e7ZLxkn9BhSSB5m7YP2Qdw2IrB1eC_361Omyn4pdq34HQ0KKQM1-7AaA==\" rel=\"nofollow noopener\" target=\"_blank\">register online<\/a>. It is recommended to register at least a day in advance. A live and archived webcast of the event will be available on the \u201cEvents\u201d section of the MaxCyte website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=bhNaPbpUme4Yx3wSRENYR7ZE1JUdWousqmmpnMoIgYPq0PGMpzxKBktEW-zK2mp5AOKG2S-N4H2rpMN3rqJJ0Q16_bizjBshZOM-iHtVLMT6bRq0UxMq9d-mgD5RfP03\" rel=\"nofollow noopener\" target=\"_blank\">https:\/\/investors.maxcyte.com\/<\/a>.<\/p>\n<p>Company management will also participate in the following investor conferences:<\/p>\n<ul type=\"disc\">\n<li>BIO CEO &amp; Investor Conference <br \/>Tuesday, February 7<sup>th<\/sup> at 3:15 p.m. Eastern Time<\/li>\n<\/ul>\n<ul type=\"disc\">\n<li>BTIG MedTech, Digital Health, Life Science &amp; Diagnostic Tools Conference<br \/>Tuesday, February 14<sup>th<\/sup><\/li>\n<\/ul>\n<ul type=\"disc\">\n<li>43<sup>rd<\/sup> Annual Cowen Healthcare Conference <br \/>Tuesday, March 7<sup>th<\/sup> at 11:10 a.m. Eastern Time<\/li>\n<\/ul>\n<p>A live and archived webcast of the Cowen presentation will be available on the \u201cEvents\u201d section of the MaxCyte investor relations website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=bhNaPbpUme4Yx3wSRENYR7ZE1JUdWousqmmpnMoIgYOmkjS9qRCwjZ5Mj_SwiTtXmF0etS6kEl3z3DhQwo13A_GHNkkzfn-dGM7d-2dOLr-I1eMJDSz-Hllx_vV7ewbT\" rel=\"nofollow noopener\" target=\"_blank\">https:\/\/investors.maxcyte.com\/<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>About MaxCyte<\/strong><br \/>\n        <br \/>MaxCyte is a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support innovative, cell-based research. Over the past 20\u00a0years, we have developed and commercialized our proprietary Flow Electroporation\u00ae platform, which facilitates complex engineering of a wide variety of cells.\u00a0Our ExPERT\u2122 platform, which is based on our Flow Electroporation technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes: four instruments, the ATx\u2122, STx\u2122 GTx\u2122 and VLx\u2122; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a robust worldwide intellectual property portfolio.<\/p>\n<p align=\"justify\">\n        <strong>MaxCyte Contacts:<\/strong>\n      <\/p>\n<p>\n        <strong><br \/>\n          <em>US IR Adviser<\/em><br \/>\n        <\/strong><br \/>\n        <br \/>\n        <strong><br \/>\n          <em>Gilmartin Group<\/em><br \/>\n        <\/strong><br \/>\n        <br \/>David Deuchler, CFA<br \/>+1 415-937-5400<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=bLoWhK4PIW36GVQdZK81ySSx6F5HtEfiRcmHo16SNfklRxQnUqQVZtCJUJeZifpCq_G1lB130zn2ValcxGMTBQ==\" rel=\"nofollow noopener\" target=\"_blank\">ir@maxcyte.com<\/a><\/p>\n<p>\n        <strong><br \/>\n          <em>Nominated Adviser and Joint Corporate Broker<\/em><br \/>\n        <\/strong><br \/>\n        <br \/>\n        <strong><br \/>\n          <em>Panmure Gordon<\/em><br \/>\n        <\/strong><br \/>\n        <br \/>Emma Earl \/ Freddy Crossley<br \/>Corporate Broking<br \/>Rupert Dearden<br \/>+44 (0)20 7886 2500<\/p>\n<p>\n        <strong><br \/>\n          <em>UK IR Adviser<\/em><br \/>\n        <\/strong><br \/>\n        <br \/>\n        <strong><br \/>\n          <em>Consilium Strategic Communications<\/em><br \/>\n        <\/strong><br \/>\n        <br \/>Mary-Jane Elliott \/ Chris Welsh<br \/>+44 (0)203 709 5700<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=eQkABRulkK9A_oKCg9H-Wb4c8o-lvxO0XJ3rzHQbKC2KYM9heOoHHCK1P6OGKs0i_1X_VPt08ZKK8KZ361gHvVj766EldIxOa1JfW58YDUL57_hz8cw6ZyZAGZdZC8Lp\" rel=\"nofollow noopener\" target=\"_blank\"><u>maxcyte@consilium-comms.com<\/u><\/a><\/p>\n<p \/>\n      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODczOTk0MyM1MzgzODIxIzIyMDUxNzg=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/ZjUyMmU2YjQtYTc2NS00MjI1LTg0NzMtNTE4OTM4MjM2Y2M5LTEyMTY3MzE=\/tiny\/MaxCyte-Inc.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>ROCKVILLE, Md., Feb. 01, 2023 (GLOBE NEWSWIRE) &#8212; MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support innovative cell-based research, today announced that it will release financial results for the fourth quarter and full year 2022 after the U.S. market close on Wednesday, March 15th, 2023. Company management will host a conference call to discuss financial results at 4:30 p.m. Eastern Time. Earnings Conference Call Details Investors interested in listening to the conference call are required to register online. It is recommended to register at least a day in advance. A live and archived webcast of the event will be &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-to-report-fourth-quarter-and-full-year-2022-financial-results-on-march-15-2023-and-participate-in-upcoming-investor-conferences\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;MaxCyte to Report Fourth Quarter and Full Year 2022 Financial Results on March 15, 2023 and Participate in Upcoming Investor Conferences&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-727872","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>MaxCyte to Report Fourth Quarter and Full Year 2022 Financial Results on March 15, 2023 and Participate in Upcoming Investor Conferences - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-to-report-fourth-quarter-and-full-year-2022-financial-results-on-march-15-2023-and-participate-in-upcoming-investor-conferences\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"MaxCyte to Report Fourth Quarter and Full Year 2022 Financial Results on March 15, 2023 and Participate in Upcoming Investor Conferences - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"ROCKVILLE, Md., Feb. 01, 2023 (GLOBE NEWSWIRE) &#8212; MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support innovative cell-based research, today announced that it will release financial results for the fourth quarter and full year 2022 after the U.S. market close on Wednesday, March 15th, 2023. Company management will host a conference call to discuss financial results at 4:30 p.m. Eastern Time. Earnings Conference Call Details Investors interested in listening to the conference call are required to register online. It is recommended to register at least a day in advance. A live and archived webcast of the event will be &hellip; Continue reading &quot;MaxCyte to Report Fourth Quarter and Full Year 2022 Financial Results on March 15, 2023 and Participate in Upcoming Investor Conferences&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-to-report-fourth-quarter-and-full-year-2022-financial-results-on-march-15-2023-and-participate-in-upcoming-investor-conferences\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-02-01T21:34:57+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODczOTk0MyM1MzgzODIxIzIyMDUxNzg=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maxcyte-to-report-fourth-quarter-and-full-year-2022-financial-results-on-march-15-2023-and-participate-in-upcoming-investor-conferences\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maxcyte-to-report-fourth-quarter-and-full-year-2022-financial-results-on-march-15-2023-and-participate-in-upcoming-investor-conferences\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"MaxCyte to Report Fourth Quarter and Full Year 2022 Financial Results on March 15, 2023 and Participate in Upcoming Investor Conferences\",\"datePublished\":\"2023-02-01T21:34:57+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maxcyte-to-report-fourth-quarter-and-full-year-2022-financial-results-on-march-15-2023-and-participate-in-upcoming-investor-conferences\\\/\"},\"wordCount\":400,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maxcyte-to-report-fourth-quarter-and-full-year-2022-financial-results-on-march-15-2023-and-participate-in-upcoming-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODczOTk0MyM1MzgzODIxIzIyMDUxNzg=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maxcyte-to-report-fourth-quarter-and-full-year-2022-financial-results-on-march-15-2023-and-participate-in-upcoming-investor-conferences\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maxcyte-to-report-fourth-quarter-and-full-year-2022-financial-results-on-march-15-2023-and-participate-in-upcoming-investor-conferences\\\/\",\"name\":\"MaxCyte to Report Fourth Quarter and Full Year 2022 Financial Results on March 15, 2023 and Participate in Upcoming Investor Conferences - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maxcyte-to-report-fourth-quarter-and-full-year-2022-financial-results-on-march-15-2023-and-participate-in-upcoming-investor-conferences\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maxcyte-to-report-fourth-quarter-and-full-year-2022-financial-results-on-march-15-2023-and-participate-in-upcoming-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODczOTk0MyM1MzgzODIxIzIyMDUxNzg=\",\"datePublished\":\"2023-02-01T21:34:57+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maxcyte-to-report-fourth-quarter-and-full-year-2022-financial-results-on-march-15-2023-and-participate-in-upcoming-investor-conferences\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maxcyte-to-report-fourth-quarter-and-full-year-2022-financial-results-on-march-15-2023-and-participate-in-upcoming-investor-conferences\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maxcyte-to-report-fourth-quarter-and-full-year-2022-financial-results-on-march-15-2023-and-participate-in-upcoming-investor-conferences\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODczOTk0MyM1MzgzODIxIzIyMDUxNzg=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODczOTk0MyM1MzgzODIxIzIyMDUxNzg=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maxcyte-to-report-fourth-quarter-and-full-year-2022-financial-results-on-march-15-2023-and-participate-in-upcoming-investor-conferences\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MaxCyte to Report Fourth Quarter and Full Year 2022 Financial Results on March 15, 2023 and Participate in Upcoming Investor Conferences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"MaxCyte to Report Fourth Quarter and Full Year 2022 Financial Results on March 15, 2023 and Participate in Upcoming Investor Conferences - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-to-report-fourth-quarter-and-full-year-2022-financial-results-on-march-15-2023-and-participate-in-upcoming-investor-conferences\/","og_locale":"en_US","og_type":"article","og_title":"MaxCyte to Report Fourth Quarter and Full Year 2022 Financial Results on March 15, 2023 and Participate in Upcoming Investor Conferences - Market Newsdesk","og_description":"ROCKVILLE, Md., Feb. 01, 2023 (GLOBE NEWSWIRE) &#8212; MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support innovative cell-based research, today announced that it will release financial results for the fourth quarter and full year 2022 after the U.S. market close on Wednesday, March 15th, 2023. Company management will host a conference call to discuss financial results at 4:30 p.m. Eastern Time. Earnings Conference Call Details Investors interested in listening to the conference call are required to register online. It is recommended to register at least a day in advance. A live and archived webcast of the event will be &hellip; Continue reading \"MaxCyte to Report Fourth Quarter and Full Year 2022 Financial Results on March 15, 2023 and Participate in Upcoming Investor Conferences\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-to-report-fourth-quarter-and-full-year-2022-financial-results-on-march-15-2023-and-participate-in-upcoming-investor-conferences\/","og_site_name":"Market Newsdesk","article_published_time":"2023-02-01T21:34:57+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODczOTk0MyM1MzgzODIxIzIyMDUxNzg=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-to-report-fourth-quarter-and-full-year-2022-financial-results-on-march-15-2023-and-participate-in-upcoming-investor-conferences\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-to-report-fourth-quarter-and-full-year-2022-financial-results-on-march-15-2023-and-participate-in-upcoming-investor-conferences\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"MaxCyte to Report Fourth Quarter and Full Year 2022 Financial Results on March 15, 2023 and Participate in Upcoming Investor Conferences","datePublished":"2023-02-01T21:34:57+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-to-report-fourth-quarter-and-full-year-2022-financial-results-on-march-15-2023-and-participate-in-upcoming-investor-conferences\/"},"wordCount":400,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-to-report-fourth-quarter-and-full-year-2022-financial-results-on-march-15-2023-and-participate-in-upcoming-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODczOTk0MyM1MzgzODIxIzIyMDUxNzg=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-to-report-fourth-quarter-and-full-year-2022-financial-results-on-march-15-2023-and-participate-in-upcoming-investor-conferences\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-to-report-fourth-quarter-and-full-year-2022-financial-results-on-march-15-2023-and-participate-in-upcoming-investor-conferences\/","name":"MaxCyte to Report Fourth Quarter and Full Year 2022 Financial Results on March 15, 2023 and Participate in Upcoming Investor Conferences - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-to-report-fourth-quarter-and-full-year-2022-financial-results-on-march-15-2023-and-participate-in-upcoming-investor-conferences\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-to-report-fourth-quarter-and-full-year-2022-financial-results-on-march-15-2023-and-participate-in-upcoming-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODczOTk0MyM1MzgzODIxIzIyMDUxNzg=","datePublished":"2023-02-01T21:34:57+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-to-report-fourth-quarter-and-full-year-2022-financial-results-on-march-15-2023-and-participate-in-upcoming-investor-conferences\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-to-report-fourth-quarter-and-full-year-2022-financial-results-on-march-15-2023-and-participate-in-upcoming-investor-conferences\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-to-report-fourth-quarter-and-full-year-2022-financial-results-on-march-15-2023-and-participate-in-upcoming-investor-conferences\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODczOTk0MyM1MzgzODIxIzIyMDUxNzg=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODczOTk0MyM1MzgzODIxIzIyMDUxNzg="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-to-report-fourth-quarter-and-full-year-2022-financial-results-on-march-15-2023-and-participate-in-upcoming-investor-conferences\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"MaxCyte to Report Fourth Quarter and Full Year 2022 Financial Results on March 15, 2023 and Participate in Upcoming Investor Conferences"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/727872","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=727872"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/727872\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=727872"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=727872"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=727872"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}